脊髓损伤后早期小鼠肠道功能的变化

目的探讨脊髓损伤后短期内小鼠肠道功能的变化。方法将105只昆明种小鼠随机分为正常组(A组,n=30)、假手术组(B组,n=30)和模型组(C组,n=45)。A组不作处理,B组仅暴露脊髓,不夹持。C组采用动脉瘤夹夹持T10处脊髓,复制脊髓损伤模型。分别于术后12 h、24 h、48 h测定小鼠回肠肌电慢波及平滑肌收缩力,并做回肠HE染色。结果脊髓损伤后12 h、24h、48 h,C组小鼠肌电频率和振幅低于A组和B组(P0.05),收缩力振幅低于A组和B组(P0.05),但24 h、48 h后收缩力频率高于A组和B组(P0.05)。C组各时间点肠黏膜评分均较A组和B组高(P0.05)。结论小鼠脊髓损伤后早期,肠道平滑肌肌电活动减弱,收缩力减小,肠黏膜轻度损伤。     

Structure-Based Design of GNE-495, a Potent and Selective MAP4K4 Inhibitor with Efficacy in Retinal Angiogenesis

相似文献   

扶他林治疗心脏电除颤所致电灼伤的疗效观察

目的观察扶他林对心脏电除颤所致电灼伤的治疗效果及安全性。方法 2011年1月至2014年12月在我院就诊的因电除颤引起的皮肤电灼伤患者66例,按照不同的治疗方法随机分为硫酸镁湿敷组、扶他林治疗组,每组33例。硫酸镁组采用50%硫酸镁湿敷,3次/d,连续5~7 d;扶他林组在局部皮肤发红处涂抹薄层扶他林,3次/d,连续5~7 d。比较两组的治疗效果及安全性。结果硫酸镁湿敷组显效13例(39.4%),有效15例(45.6%),无效5例(15.0%);扶他林治疗组显效25例(75.8%),有效8例(24.2%),无效0例。扶他林治疗组疗效优于硫酸镁湿敷组,两组比较差异具有统计学意义(P<0.05)。两组均无药物不良反应发生。结论扶他林治疗心脏电除颤所致电灼伤的效果好于硫酸镁湿敷,且无明显的药物不良反应,是治疗心脏电除颤所致电灼伤的一种非常有效且安全的药物。     

Folate Deficiency Decreases Apoptosis of Endometrium Decidual Cells in Pregnant Mice via the Mitochondrial Pathway

It is well known that maternal folate deficiency results in adverse pregnancy outcomes. In addition to aspects in embryonic development, maternal uterine receptivity and the decidualization of stromal cells is also very important for a successful pregnancy. In this study, we focused on endometrium decidualization and investigated whether apoptosis, which is essential for decidualization, was impaired. Flow cytometry and TUNEL detection revealed that apoptosis of mouse endometrium decidual cells was suppressed in the dietary folate-deficient group on Days 7 and 8 of pregnancy (Day 1 = vaginal plug) when decidua regression is initiated. The endometrium decidual tissue of the folate deficiency group expressed less Bax compared to the normal diet group while they had nearly equal expression of Bcl2 protein. Further examination revealed that the mitochondrial transmembrane potential (ΔΨm) decreased, and the fluorescence of diffuse cytoplasmic cytochrome c protein was detected using laser confocal microscopy in normal decidual cells. However, no corresponding changes were observed in the folate-deficient group. Western blotting analyses confirmed that more cytochrome c was released from mitochondria in normal decidual cells. Taken together, these results demonstrated that folate deficiency could inhibit apoptosis of decidual cells via the mitochondrial apoptosis pathway, thereby restraining decidualization of the endometrium and further impairing pregnancy.     

Phase I Study of Nintedanib Incorporating Dynamic Contrast‐Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors

Background.

This open-label phase I dose-escalation study investigated the safety, efficacy, pharmacokinetics (PK), and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) effects of the oral angiokinase inhibitor nintedanib in patients with advanced solid tumors.

Methods.

Nintedanib was administered once daily continuously, starting at 100 mg and later amended to allow evaluation of 250 mg b.i.d. The primary endpoint was maximum tolerated dose (MTD). DCE-MRI studies were performed at baseline and on days 2 and 28.

Results.

Fifty-one patients received nintedanib 100–450 mg once daily (n = 40) or 250 mg b.i.d. (n = 11). Asymptomatic reversible liver enzyme elevations (grade 3) were dose limiting in 2 of 5 patients at 450 mg once daily. At 250 mg b.i.d., 2 of 11 patients experienced dose-limiting toxicity (grade 3 liver enzyme elevation and gastrointestinal symptoms). Common toxicities included fatigue, diarrhea, nausea, vomiting, and abdominal pain (mainly grade ≤2). Among 45 patients, 22 (49%) achieved stable disease; 7 remained on treatment for >6 months. DCE-MRI of target lesions revealed effects in some patients at 200 and ≥400 mg once daily.

Conclusion.

Nintedanib is well tolerated by patients with advanced solid malignancies, with MTD defined as 250 mg b.i.d., and can induce changes in DCE-MRI. Disease stabilization >6 months was observed in 7 of 51 patients.     

PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism

PTEN has been studied in several tumor models as a tumor suppressor. In this study, we explored the role of PTEN in the inhibition state of polarized M2 subtype of macrophage in tumor microenvironment (TME) and the underlying mechanisms. To elucidate the potential effect in TME, RAW 264.7 macrophages and 4T1 mouse breast cancer cells were co-cultured to reconstruct tumor microenvironment. After PTEN was down-regulated with shRNA, the expression of CCL2 and VEGF-A, which are definited to promote the formation of M2 macrophages, have a dramatically increase on the level of both gene and protein in co-cultured RAW 264.7 macrophages. And at the same time, NHERF-1 (Na⁺/H⁺ exchanger regulating factor-1), another tumor suppressor has a similar tendency to PTEN. Q-PCR and WB results suggested that PTEN and NHERF-1 were consistent with one another no matter at mRNA or protein level when exposed to the same stimulus. Coimmunoprecipitation and immunofluorescence techniques confirmed that PTEN and NHERF-1 were coprecipitated, and NHERF-1 protein expression was properly reduced with rCCL2 effect. In addition, cell immunofluorescence images revealed a profound transferance, in co-cultured RAW 264.7 macrophages, an up-regulation of NHERF-1 could promote the PTEN marked expression on the cell membrane, and this form for the interaction was not negligible. These observations illustrate PTEN with a certain synergy of NHERF-1, as well as down-regulation of CCL2 suppressing M2 macrophage transformation pathway. The results suggest that the activation of PTEN and NHERF-1 may impede the evolution of macrophages beyond the M1 into M2 phenotype in tumor microenvironment.